Gilead Sciences Q1 earnings report is due April 24. Explore forecasts on revenue growth, EPS expectations, HIV pipeline ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. U.K drug marketing watchdog the PMCPA ruled the network login process, which directed users to Gilead’s U ...

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not ...

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

In The Handmaid’s Tale Season 6 Episode 5, ‘Janine’, Moira, June, and Luke head to Gilead, and things get deadly.

WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...

In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences, Inc. (GILD), based in Foster City, California, is a leading biopharmaceutical company focused on developing and commercializing groundbreaking therapies for diseases like HIV ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...